Loading clinical trials...

Sarizotan in Participants With Parkinson's Disease Suffering From Treatment Associated Dyskinesia | Clinical Trials | Clareo Health

COMPLETEDPHASE3

Sarizotan in Participants With Parkinson's Disease Suffering From Treatment Associated Dyskinesia

A Double-Blind, Placebo-Controlled, Multicenter, Multinational Phase III Study to Evaluate the Safety and Efficacy of Sarizotan in Patients With Parkinson's Disease Suffering From Treatment-Associated Dyskinesia

NCT00105521•EMD Serono

View on ClinicalTrials.gov

Summary

The purpose of this study is to test multiple doses of sarizotan to establish a dose with maximal safety and efficacy for treating treatment associated dyskinesia in Parkinson's disease participants.

Eligibility

Age

30 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•The participant is an out-patient
•The participant presents with a diagnosis of idiopathic Parkinson's disease
•Prior therapy with all registered Parkinsonian medication is allowed

Exclusion Criteria

•(For female participants) The participant is pregnant or lactating
•The participant is participating in another clinical study or has done so within the past 30 days
•The participant has received neurosurgical intervention related to Parkinson's disease
•The participant has relevant renal impairment
•The participant has relevant hepatic impairment
•The participant is suffering from any dementia or psychiatric illness
•The participant has a history of allergic asthma

Locations (32)

Phoenix, Arizona, United States

Scottsdale, Arizona, United States

Fayetteville, Arkansas, United States

Fountain Valley, California, United States

Los Angeles, California, United States

Fort Lauderdale, Florida, United States

Hollywood, Florida, United States

Ocala, Florida, United States

Key Dates

Start Date

September 30, 2004

Primary Completion Date

March 31, 2006

Completion Date

March 31, 2006

Last Updated

April 2, 2018

Enrollment

398

ACTUAL participants

Conditions

Parkinson's DiseaseDyskinesia

Interventions

Sarizotan

DRUG

Placebo

DRUG

Deep Brain Stimulation Therapy in Movement Disorders

NCT02119611

Parkinson's Disease

View study

RECRUITINGPHASE1

Research Into the Safety of a New Agent (VT-5006) in People With and Without Parkinson's Disease

NCT07310264

Healthy Volunteers (HV)Parkinson's Disease (PD)

View study

RECRUITINGNA

Adaptive DBS Algorithm for Personalized Therapy in Parkinson's Disease (ADAPT-PD) China Study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: April 2, 2018Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Sarizotan in Participants With Parkinson's Disease Suffering From Treatment Associated Dyskinesia

Inclusion Criteria

Exclusion Criteria

Deep Brain Stimulation Therapy in Movement Disorders

Research Into the Safety of a New Agent (VT-5006) in People With and Without Parkinson's Disease

Adaptive DBS Algorithm for Personalized Therapy in Parkinson's Disease (ADAPT-PD) China Study

A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease

Effect of Striatal Temporal Interference Stimulation on Language Processing in Neurodegenerative Diseases

SAD Study in Patients With Parkinson's Disease and Motor Fluctuations